Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor), also known as TNFRSF18, CD357, or AITR, is a type I transmembrane protein and a member of the TNF receptor superfamily. It is constitutively expressed on regulatory T cells and upregulated on activated T cells. GITR interacts with its ligand GITRL, primarily expressed on antigen-presenting cells. GITR signaling plays a complex role in regulating immune responses, acting as a co-stimulatory signal for effector T cells, modulating the suppressive function of regulatory T cells, and regulating NK cell activity. It is implicated in cancer immunity, autoimmunity, inflammation, and cardiovascular disease.
GITR engagement provides co-stimulatory signals, modulates regulatory T cell suppression, and/or regulates NK cell activity depending on the cell type and context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR).